U.S. FDA approves Boehringer's JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1 Approval is based on results from two clinical trials, which showed reduction in Forced Vital Capaci
(Financial Post, 2025-10-09T10:10:20Z)